Updated: Roche pays Alnylam $310M cash to partner on RNAi candidate for heart disease

Amber Tong

Roche is buying into a mid-stage cardiovascular drug candidate out of Alnylam’s RNAi platform in a deal that starts with $310 million upfront and could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Roche pays Alnylam $310M cash to partner on RNAi candidate for heart disease

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche buys out CAR-T partner Poseida for $1B upfront

Bristol Myers reveals more job cuts in New Jersey

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Up­dat­ed: Roche pays Al­ny­lam $310M cash to part­ner on RNAi can­di­date for heart dis­ease

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Updated: Roche pays Alnylam $310M cash to partner on RNAi candidate for heart disease

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche buys out CAR-T partner Poseida for $1B upfront

Bristol Myers reveals more job cuts in New Jersey

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives